HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Circulars
Returns on Share Capital
Notice(s) of Replacement of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Latest News
Mar
22
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
22
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2022
Mar
22
VOLUNTARY ANNOUNCEMENT - SARS-CoV-2 mRNA VACCINE (SYS6006) INCLUDED FOR EMERGENCY USE IN CHINA
/?php echo file_get_contents("https://www.irasia.com/cgi-local/adaptation/listco/hk/cspc/data.cgi?id=cspc&p=data&t=aclp&layout=home&n=3"); ?>
Financial Reports
2022 Interim Report
Highlight - 9M2022
Revenue
RMB23,496mn, +13.8%
Underlying profit attributable to shareholders
RMB4,624mn, +14.5%
Profit attributable to shareholders
RMB4,468mn, +3.1%
Basic earnings per share
RMB37.49 cents, +3.4%
Key Products
Finished drugs
Bulk drugs
NBP (soft capsules)
NBP (injections)
Oulaining (capsules)
Oulaining (lyophilised powder for injections)
Enxi
Duomeisu
Jinyouli
Keaili
Shuluoke
Nuomoling
Weihong
Xinweihong
Xuanning
Encun
Qixiao
Linmeixin
Shuanglexin
Gubang
Gubangjia
Gaoshunsong
Debixin
Qimaite
Antibiotics
Vitamin C
Caffeine